Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 25;20(5):1475-1479.
doi: 10.31557/APJCP.2019.20.5.1475.

Clinical Studies Investigating the Use of Leuprorelin in Breast Cancer Patients from Asia

Wonshik Han  1 , Hyun Jo Youn  2
Affiliations
Review

Clinical Studies Investigating the Use of Leuprorelin in Breast Cancer Patients from Asia

Wonshik Han et al. Asian Pac J Cancer Prev. .

Abstract

Leuprorelin is a synthetic analogue of naturally occurring gonadotropin-releasing hormone. It is currently approved in the United States, Europe and Asia and has indications in advanced prostate cancer, endometriosis, breast cancer and precocious puberty. This review examined clinical trials of leuprorelin in women with breast cancer in Asia. Methods: Four studies were identified, involving 999 premenopausal females with breast cancer. Leuprorelin was administered subcutaneously at doses of 3.75 mg every 4 weeks, 11.25 mg every 12 weeks or 22.5 mg every 24 weeks in addition to either adjuvant chemotherapy or hormonal therapy. Results: Leuprorelin was shown to preserve ovarian function, reduce symptoms of ovarian failure, the occurrence of early menopause, and the time to resumption of menses. Leuprorelin-related adverse events included hot flush, mood swings and urogenital symptoms. Conclusion: Clinical studies in breast cancer patients from Asia have primarily investigated the effect of leuprorelin on the protection of ovarian function in patients who receive chemotherapy, assessed the ability of leuprorelin to suppress serum estradiol to menopausal levels, or to determine the efficacy and safety of leuprorelin in daily medical practice.

Keywords: Breast neoplasms; menopause; premenopause; leuprolide; fertility.

PubMed Disclaimer

References

    1. Asthana S, Chauhan S, Labani S. Breast and cervical cancer risk in India:An Update. Indian J Public Health. 2014;58:5–10. - PubMed
    1. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in Rhesus Monkeys. Biol Reprod. 1995;52:365–72. - PubMed
    1. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-Luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female Rats. Br J Cancer. 1990;61:861–5. - PMC - PubMed
    1. ClinicalTrials.gov. A PHASE 3 COMPARATIVE STUDY OF TAP-144-SR(6M) IN Postoperative and Hormone Therapy-Naïve Patients with Premenopausal Breast Cancer. NCT01546649. [Accessed 1 November 2017]. Accessed via https://clinicaltrials.gov/ct2/show/study/NCT01546649?term=A+Phase+3+Com... .
    1. ClinicalTrials.gov. Leuprorelin Acetate Sr 11.25 Mg For Injection Specified Drug-Use Survey “Long-Term Use Survey On Premenopausal Breast Cancer Patients (96 WEEKS). NCT02154139. [Accessed 1 November 2017]. Accessed via https://clinicaltrials.gov/ct2/show/results/NCT02154139?term=NCT02154139... .